Washington is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Bellevue. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379
Recruiting
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/20/2025
Locations: Core Clinical Research, Everett, Washington
Conditions: Major Depressive Disorder
Register for Updates
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931
Recruiting
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Medical Oncology Associated, PS (dba Summit Cancer Centers), Spokane, Washington
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
A Study of YL201 in Patients with Advanced Solid Tumors
NCT05434234
Recruiting
This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Medical Oncology Associates and Summit Cancer Centers, Spokane, Washington
Conditions: Advanced Solid Tumor
Register for Updates
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/20/2025
Locations: MultiCare Institute - Mary Bridge Children's Neurology, Tacoma, Washington
Conditions: Partial Epilepsy
Register for Updates
Cephea Early Feasibility Study
NCT05061004
Recruiting
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Mitral Regurgitation
Register for Updates
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
NCT05008276
Recruiting
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better unde... Read More
Gender:
ALL
Ages:
Between 8 years and 14 years
Trial Updated:
03/20/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes, Kidney Hypoxia, Puberty
Register for Updates
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: University of Washington (UW) - Harborview Medical Center (HMC) - Hepatitis and Liver Clinic, Seattle, Washington
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
A Study of GlcNAc on Tear Production in NGLY1-CDDG
NCT05402345
Recruiting
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
Gender:
ALL
Ages:
Between 1 year and 60 years
Trial Updated:
03/19/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: NGLY1 Deficiency
Register for Updates
The Tick App: Changing Behaviors With Educational Messaging
NCT06880692
Recruiting
The goal of this work is to evaluate the use of ecological momentary assessments as a tool to assess risk and risk factors for tick encounters and tick-borne diseases. This study will be conducted across the United States, with a focus the upper Midwest and Northeast and with a focus on Wisconsin and will enroll up to 1000 people.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Washington State University, Pullman, Washington
Conditions: Tick Bites
Register for Updates
Phase 2 Seattle Dietary Biomarkers Development Center
NCT06656338
Recruiting
The Seattle Dietary Biomarker Development Center (S-DBDC) aims to advance the science of measuring dietary intake by identification and validation of dietary biomarkers that improve upon self-reported diet. To accomplish this mission, the Seattle DBDC will carry out controlled feeding studies in healthy human volunteers. Metabolomics assays will be conducted on blood and urine specimens collected during the feeding studies for biomarker identification. Stool samples will be collected and archive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Healthy Adults
Register for Updates
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/18/2025
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Major Depressive Disorder
Register for Updates
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
03/18/2025
Locations: Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates